An Evaluation of Psilocybin's Effect on Cardiac Repolarization

This double-blind placebo-controlled trial (n=36) investigates the effects of psilocybin on heart health (Cardiac Repolarization), the dosing includes one (not defined) extra high dose of psilocybin (supratherapeutic).

Topic Safety

Compound Psilocybin

Country United States of America

Visit trial

Status Active, not recruiting

Results Published No

Start date 22 June 2022

End date 01 June 2023

Chance of happening 100%

Phase Phase II

Design Blinded

Type Interventional

Generation First

Participants 36

Sex All

Age 18- 65

Therapy No

Trial Details

This study will be a double-blind, single-dose, randomized, placebo-controlled, 4-treatment, 4-period, 12-sequence crossover design in 36 healthy volunteers (adult male and/or female subjects). Subjects will be randomly assigned to 1 of 12 different treatment administration sequences, whereby each sequence will include 3 double-blind treatments (therapeutic dose of psilocybin, supratherapeutic dose of psilocybin, and placebo) and 1 open-label positive control treatment (moxifloxacin).

NCT Number NCT05478278

Sponsors & Collaborators

Usona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.